Researchers develop next-generation CAR T cells that show stronger, safer response in animal models
Researchers from the Keck School of Medicine of USC have developed a new type of…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
ASH 2025: Milder chemo works for rare, aggressive lymphoma
Most patients with a rare and aggressive form of large B-cell lymphoma can safely receive…
FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
On December 12, 2025, the Food and Drug Administration approved niraparib and abiraterone acetate with prednisone…
Targeting B-cells may boost immunotherapy in liver cancer treatment
Scientists have identified a promising strategy to improve liver cancer immunotherapy: targeting B-cells. While immunotherapy has transformed cancer treatment…
FDA approves epcoritamab-bysp for follicular lymphoma indications
On November 18, 2025, the Food and Drug Administration approved epcoritamab-bysp with lenalidomide and rituximab for…
SABCS 2025: Sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer
Skipping sentinel lymph node biopsy (SLNB) in patients with clinically node-negative, hormonal receptor (HR)-positive, HER2-negative…
New research discovers dementia-linked protein’s role in DNA mistakes
New Houston Methodist research has revealed that a protein associated with neurodegenerative diseases such as dementia and amyotrophic lateral sclerosis (ALS) also plays a…
MYC targeting by omomyc synergizes with PARP inhibition and potentiates antitumour response in preclinical models of triple-negative breast cancer
Findings from a preclinical study led by VHIO’s Models of Cancer Therapies Group, directed by…
New model demonstrates how a dynamic mechanism regulates traffic through the nuclear pore complex
The nuclear pore complex (NPC) is an active and highly selective barrier that controls what…
ASH 2025: New data highlights promise of pivekimab sunirine in two aggressive blood cancers
Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing…